Laddar...
Rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen
What is already known about this subject • Rivaroxaban is a novel anticoagulant with predictable, dose-proportional pharmacokinetics and pharmacodynamics in healthy subjects. • It is in clinical development for the prevention of thromboembolic disorders in patients undergoing major orthopaedic surge...
Sparad:
| Huvudupphovsmän: | , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Blackwell Publishing Ltd
2007
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2203251/ https://ncbi.nlm.nih.gov/pubmed/17100983 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2006.02776.x |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|